Daxor Corporation (NASDAQ: DXR) Stock Competitors & Peer Comparison
See DXR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DXR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $11.57 | +2.69% | 68M | 9.47 | $1.23 | N/A |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
DXR vs ISRG Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ISRG's P/E ratio is 39.21. In terms of profitability, DXR's ROE is +0.13%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
DXR vs BDXA Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BDXA's P/E ratio is 45.70. In terms of profitability, DXR's ROE is +0.13%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
DXR vs BDX Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BDX's P/E ratio is 14.30. In terms of profitability, DXR's ROE is +0.13%, compared to BDX's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
DXR vs RMD Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas RMD's P/E ratio is 21.32. In terms of profitability, DXR's ROE is +0.13%, compared to RMD's ROE of +0.24%. Regarding short-term risk, DXR is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
DXR vs MDLN Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas MDLN's P/E ratio is 23.53. In terms of profitability, DXR's ROE is +0.13%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
DXR vs WST Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas WST's P/E ratio is 42.93. In terms of profitability, DXR's ROE is +0.13%, compared to WST's ROE of +0.19%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
DXR vs HOLX Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.13%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
DXR vs SOLV Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas SOLV's P/E ratio is 12.69. In terms of profitability, DXR's ROE is +0.13%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for DXR.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
DXR vs BDXB Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.13%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
DXR vs BAX Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BAX's P/E ratio is 11.39. In terms of profitability, DXR's ROE is +0.13%, compared to BAX's ROE of -0.17%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
DXR vs AVTR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas AVTR's P/E ratio is 18.15. In terms of profitability, DXR's ROE is +0.13%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
DXR vs COO Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas COO's P/E ratio is 11.68. In terms of profitability, DXR's ROE is +0.13%, compared to COO's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
DXR vs RGEN Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas RGEN's P/E ratio is 97.07. In terms of profitability, DXR's ROE is +0.13%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
DXR vs ATR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ATR's P/E ratio is 21.79. In terms of profitability, DXR's ROE is +0.13%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
DXR vs BLCO Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BLCO's P/E ratio is 26.52. In terms of profitability, DXR's ROE is +0.13%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
DXR vs STVN Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas STVN's P/E ratio is 32.57. In terms of profitability, DXR's ROE is +0.13%, compared to STVN's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
DXR vs TFX Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas TFX's P/E ratio is 14.75. In terms of profitability, DXR's ROE is +0.13%, compared to TFX's ROE of -0.32%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
DXR vs MMSI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas MMSI's P/E ratio is 22.04. In terms of profitability, DXR's ROE is +0.13%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
DXR vs NVST Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NVST has a market cap of 4B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NVST's P/E ratio is 16.85. In terms of profitability, DXR's ROE is +0.13%, compared to NVST's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
DXR vs ICUI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ICUI's P/E ratio is 19.46. In terms of profitability, DXR's ROE is +0.13%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, DXR is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
DXR vs PLSE Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas PLSE's P/E ratio is -46.78. In terms of profitability, DXR's ROE is +0.13%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
DXR vs ATRC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, DXR's ROE is +0.13%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
DXR vs XRAY Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas XRAY's P/E ratio is 6.87. In terms of profitability, DXR's ROE is +0.13%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, DXR is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
DXR vs LMAT Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas LMAT's P/E ratio is 29.69. In terms of profitability, DXR's ROE is +0.13%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
DXR vs BLFS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BLFS's P/E ratio is -172.18. In terms of profitability, DXR's ROE is +0.13%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, DXR is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
DXR vs AZTA Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas AZTA's P/E ratio is 78.64. In terms of profitability, DXR's ROE is +0.13%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
DXR vs KMTS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas KMTS's P/E ratio is -9.50. In terms of profitability, DXR's ROE is +0.13%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
DXR vs STAA Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas STAA's P/E ratio is 39.38. In terms of profitability, DXR's ROE is +0.13%, compared to STAA's ROE of +0.01%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
DXR vs ATRI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.13%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
DXR vs ANGO Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ANGO's P/E ratio is -40.21. In terms of profitability, DXR's ROE is +0.13%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, DXR is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
DXR vs SMTI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas SMTI's P/E ratio is -585.17. In terms of profitability, DXR's ROE is +0.13%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, DXR is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
DXR vs EMBC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas EMBC's P/E ratio is 1.96. In terms of profitability, DXR's ROE is +0.13%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, DXR is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
DXR vs NNNN Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NNNN's P/E ratio is 79.62. In terms of profitability, DXR's ROE is +0.13%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
DXR vs OSUR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas OSUR's P/E ratio is -5.01. In terms of profitability, DXR's ROE is +0.13%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
DXR vs UTMD Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas UTMD's P/E ratio is 22.08. In terms of profitability, DXR's ROE is +0.13%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
DXR vs PDEX Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas PDEX's P/E ratio is 16.20. In terms of profitability, DXR's ROE is +0.13%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
DXR vs KRMD Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas KRMD's P/E ratio is -79.00. In terms of profitability, DXR's ROE is +0.13%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, DXR is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
DXR vs STXS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas STXS's P/E ratio is -7.76. In terms of profitability, DXR's ROE is +0.13%, compared to STXS's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
DXR vs AKYA Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.13%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
DXR vs STSS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.13%, compared to STSS's ROE of -1.54%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
DXR vs OMIC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.13%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
DXR vs IGAP Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.13%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
DXR vs NEPH Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NEPH's P/E ratio is 71.50. In terms of profitability, DXR's ROE is +0.13%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
DXR vs POCI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas POCI's P/E ratio is -6.68. In terms of profitability, DXR's ROE is +0.13%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
DXR vs HBIO Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas HBIO's P/E ratio is -22.17. In terms of profitability, DXR's ROE is +0.13%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, DXR is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
DXR vs MLSS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas MLSS's P/E ratio is -8.02. In terms of profitability, DXR's ROE is +0.13%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
DXR vs SDC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.13%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
DXR vs IVC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.13%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
DXR vs RVP Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas RVP's P/E ratio is -5.67. In terms of profitability, DXR's ROE is +0.13%, compared to RVP's ROE of -0.05%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
DXR vs BNGO Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas BNGO's P/E ratio is -0.36. In terms of profitability, DXR's ROE is +0.13%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, DXR is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
DXR vs ZJYL Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, DXR's ROE is +0.13%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
DXR vs RGNT Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas RGNT's P/E ratio is -0.07. In terms of profitability, DXR's ROE is +0.13%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
DXR vs CUPR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas CUPR's P/E ratio is -2.12. In terms of profitability, DXR's ROE is +0.13%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, DXR is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
DXR vs FEMY Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas FEMY's P/E ratio is -0.57. In terms of profitability, DXR's ROE is +0.13%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, DXR is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
DXR vs LUCY Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas LUCY's P/E ratio is -0.49. In terms of profitability, DXR's ROE is +0.13%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
DXR vs NSTG Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.13%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
DXR vs POAI Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.13%, compared to POAI's ROE of -21.19%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
DXR vs MHUA Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.13%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
DXR vs NXGL Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NXGL's P/E ratio is -0.40. In terms of profitability, DXR's ROE is +0.13%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
DXR vs GMVD Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.13%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
DXR vs GMVDW Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.13%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
DXR vs AVGR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.13%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
DXR vs NXGLW Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.13%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
DXR vs LUCYW Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.13%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
Invuity, Inc. (NASDAQ: IVTY)
DXR vs IVTY Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas IVTY's P/E ratio is -3.80. In terms of profitability, DXR's ROE is +0.13%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
DXR vs HRC Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.13%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
DXR vs IIN Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.13%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
DXR vs APR Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.13%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
DXR vs ATRS Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.13%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
DXR vs ALOG Comparison September 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 68M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $11.57 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 9.47, whereas ALOG's P/E ratio is 40.93. In terms of profitability, DXR's ROE is +0.13%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here